Your browser doesn't support javascript.
loading
A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development.
Tang, Yuhong; Fan, Yujuan; Wang, Yiming; Wang, Dong; Huang, Qingyu; Chen, Tongqing; Cao, Xinyue; Wen, Cailing; Shen, Xiaoyan; Li, Jian; You, Yan.
Afiliación
  • Tang Y; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, China.
  • Fan Y; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, China.
  • Wang Y; Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China.
  • Wang D; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, China.
  • Huang Q; Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China.
  • Chen T; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, China.
  • Cao X; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, China.
  • Wen C; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, China.
  • Shen X; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, China. Electronic address: shxiaoy@fudan.edu.cn.
  • Li J; Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China. Electronic address: 13816066763@163.com.
  • You Y; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, China. Electronic address: yyou@fudan.edu.cn.
Biomed Pharmacother ; 175: 116658, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38701562
ABSTRACT
The global prevalence of nonalcoholic fatty liver disease (NAFLD) has reached 30 %, with an annual increase. The incidence of NAFLD-induced cirrhosis is rapidly rising and has become the leading indicator for liver transplantation in the US. However, there are currently no US Food and Drug Administration-approved drugs for NAFLD. Increasing evidence underscores the close association between NAFLD and bile acid metabolism disorder, highlighting the feasibility of targeting the bile acid signaling pathway for NAFLD treatment. The farnesoid X receptor (FXR) is an endogenous receptor for bile acids that exhibits favorable effects in ameliorating the metabolic imbalance of bile acids, lipid disorders, and disruption of intestinal homeostasis, all of which are key characteristics of NAFLD, making FXR a promising therapeutic target for NAFLD. The present review provides a comprehensive overview of the diverse mechanisms through which FXR improves NAFLD, with particular emphasis on its involvement in regulating bile acid homeostasis and the recent advancements in drug development targeting FXR for NAFLD treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácidos y Sales Biliares / Receptores Citoplasmáticos y Nucleares / Enfermedad del Hígado Graso no Alcohólico / Desarrollo de Medicamentos Límite: Animals / Humans Idioma: En Revista: Biomed Pharmacother Año: 2024 Tipo del documento: Article Pais de publicación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácidos y Sales Biliares / Receptores Citoplasmáticos y Nucleares / Enfermedad del Hígado Graso no Alcohólico / Desarrollo de Medicamentos Límite: Animals / Humans Idioma: En Revista: Biomed Pharmacother Año: 2024 Tipo del documento: Article Pais de publicación: Francia